TOM1L1: A Potential Drug Target and Biomarker (G10040)

Target Name: TOM1L1

NCBI ID: G10040

TOM1L1

TOM1L1: A Potential Drug Target and Biomarker

Tumor suppressor genes (TSGs) are a class of genes that are frequently mutated in cancer and are thought to play a crucial role in tumor development. TSGs are usually expressed in a limited number of cell types and are involved in various cellular processes, including cell growth, apoptosis, and angiogenesis. The discovery of TSGs has led to a new understanding of the molecular mechanisms underlying cancer and has implications for the development of new therapeutic strategies.

One of the most promising TSGs is TOM1L1, which is a gene that is expressed in a variety of tissues and is involved in the regulation of cell growth, differentiation, and apoptosis. TOM1L1 has been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers.

The potential drug targets for TOM1L1 are numerous and range from cell signaling pathways to cellular processes such as cell division, apoptosis, and angiogenesis. One of the most promising targets is the PI3K/Akt signaling pathway, which is a well-established signaling pathway that is involved in various cellular processes, including cell growth, angiogenesis, and drug resistance.

The PI3K/Akt signaling pathway is a highly validated drug target that has been targets for numerous drugs, including inhibitors of the pathway, such as inhibitors of the protein inhibitor of and activator of the PI3K/Akt signaling pathway (PI), which is a protein that inhibits the signaling pathway. In recent years, several drugs have been approved for the treatment of PI3K/Akt-related diseases, including cancer.

In addition to its potential as a drug target, TOM1L1 is also a potential biomarker for cancer. The expression of TOM1L1 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, TOM1L1 has been shown to be associated with cancer-related outcomes, including cancer-specific survival and overall survival.

The discovery of TOM1L1 as a potential drug target and biomarker has implications for the development of new therapeutic strategies for cancer. Further research is needed to fully understand the role of TOM1L1 in cancer and to identify small molecules or other compounds that can inhibit its activity. By targeting the PI3K/Akt signaling pathway, researchers may be able to develop new treatments for a variety of cancer types.

Protein Name: Target Of Myb1 Like 1 Membrane Trafficking Protein

Functions: Probable adapter protein involved in signaling pathways. Interacts with the SH2 and SH3 domains of various signaling proteins when it is phosphorylated. May promote FYN activation, possibly by disrupting intramolecular SH3-dependent interactions (By similarity)

The "TOM1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOM1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets